Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

XBRL 30 June 2020 filed with the SEC

September 16, 2020September 16, 2020 Alterity Therapeutics

XBRL 30 June 2020 filed with the SEC

Post navigation

New data independently confirms and extends laboratory findings and expands safety profile of ATH434

Alterity raises $35M in placement to international and Australian institutions and sophisticated investors.

Related Posts

Journal of Huntington’s Disease Publishes Benefits of PBT2

July 17, 2013

Prana AGM Webcast Details

November 10, 2015

Change of Company Name

April 8, 2019

Leave a Reply Cancel reply

Your email address will not be published.Required fields are marked *

Save my name, email, and website in this browser for the next time I comment.

Recent Posts

Alterity to present at the 7th International Congress of Multiple System Atrophy
Alterity Half Year Results and Investor Webcast Notification
Alterity announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson’s disease clinical trials
Quarterly Cash Flow Report
New hope in global fight against antibiotic resistant superbugs

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065